The prediction of the MGMT methylation status using MGMT-STP27 in a cohort of grade II and III gliomas (T-Glioma-II/III) with HM-450K data, determined a methylation frequency of 79 % (32/42) in grade III glioma and 86 % (25/29) in grade II. The gene discussed is MGMT; the disease is central nervous system cancer.